^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Carvykti (ciltacabtagene autoleucel)

    i
    Company:
    J&J, Legend Biotech
    Drug class:
    BCMA-targeted CAR-T immunotherapy
    Related drugs:
    Apply
    Ciltacabtagene Autoleucel in High-Risk Smoldering Multiple Myeloma (CAR-HiRiSMM) (NCT06574126)
    Phase 2
    PETHEMA Foundation
    Recruiting
    Last update posted :
    10/26/2024
    Initiation :
    09/30/2024
    Primary completion :
    09/30/2032
    Completion :
    09/30/2032
    CD4
    |
    Carvykti (ciltacabtagene autoleucel)
    CAR- PRISM (PRecision Intervention Smoldering Myeloma) (NCT05767359)
    Phase 2
    Dana-Farber Cancer Institute
    Recruiting
    Last update posted :
    06/19/2023
    Initiation :
    04/19/2023
    Primary completion :
    01/15/2026
    Completion :
    01/15/2040
    TP53
    |
    TP53 mutation • Chr t(4;14) • Chr t(14;16)
    |
    cyclophosphamide • fludarabine IV • Carvykti (ciltacabtagene autoleucel)
    A Study of LCAR-B38M CAR-T Cells, a Chimeric Antigen Receptor T-cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Chinese Participants With Relapsed or Refractory Multiple Myeloma (CARTIFAN-1) (NCT03758417)
    Phase 2
    Nanjing Legend Biotech Co.
    Recruiting
    Last update posted :
    12/28/2022
    Initiation :
    01/23/2019
    Primary completion :
    02/16/2026
    Completion :
    02/16/2026
    CD8 • IL6 • IL2RA • CD4 • IL10
    |
    Carvykti (ciltacabtagene autoleucel)